Deyaa Adib, MD, on Safety Advantages of TAC T-Cell Therapy in Solid Tumors


The chief medical officer of Triumvira Immunologics discussed how TAC01-HER2 could address unmet needs in treating solid tumors.

"The most valuable advantage we see so far would be the safety profile associated with HER2-TAC T-cells and it is very well differentiated thus far compared to approved CARs. So far we have not seen any dose limiting toxicities, cytokine release syndrome, or neurotoxicity in dose levels 1 and 2."

Triumvira Immunologics’ TAC01-HER2, a HER2-targeted T-cell antigen coupler (TAC) T-cell therapy, was well-tolerated with early signs of clinical activity. In new data from cohort 2 of the phase 1/2 TACTIC-2 study, the therapy yielded a partial response in a patient with stage 4b gastric cancer and a 75% disease control rate.

Data from the study were presented by Benjamin L. Schlechter, MD, instructor, medicine, Harvard Medical School, and Dana-Farber Cancer Institute, at the European Society for Medical Oncology (ESMO) Congress 2022, held September 9-13, in Paris, France. The trial will be enrolling in its phase 2 portion in the beginning of 2023.

CGTLive spoke with senior author Deyaa Adib, MD, chief medical officer, Triumvira Immunologics, to learn more about unmet needs in patients with solid tumors. He discussed the advantages of the TAC T-cell technology in addressing these unmet needs, including a positive safety profile with lower rates of cytokine release syndrome compared to those seen in other cell therapy trials.

Click here to read more coverage of ESMO Congress 2022.

Schlechter BL, Ileana Dumbrava EE, Olson D, et al. A phase I/II trial investigating safety and efficacy of autologous TAC T-cells targeting HER2 in relapsed or refractory solid tumors. Presented at: ESMO Congress 2022, September 9-13, Paris, France. Poster #778TiP
Related Videos
Brian Van Tine, MD, PhD, on Looking Ahead on Cell Therapy for Sarcomas
Dilsher Dhoot, MD, on a Promising Start With Diabetic Retinopathy Gene Therapy RGX-314
J. Andrew Livingston, MD, on Forging Forward With Novel Sarcoma Trials
Shankar Musunuri, PhD, on Gene Modifier Therapy vs Gene Replacement Therapy for IRDs
Pat Furlong, BSN, RN, on the State of Gene Therapy in Muscular Dystrophy
Michael Kelly, PhD, on Continuing Progress With Gene Therapy in Muscular Dystrophy
Related Content
© 2023 MJH Life Sciences

All rights reserved.